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A B S T R A C T
The mechanisms that mediate the cardioprotective action of steroid hormones in post-
menopausal women are poorly understood. To study the inter-relationship between female
steroid hormones and cardiac natriuretic peptides, plasma levels of atrial natriuretic peptide
(ANP) and brain natriuretic peptide (BNP) were measured in postmenopausal women, both
before and after oestrogen replacement therapy. A total of 22 healthy postmenopausal women
(mean age 51–9‡4–6 years) were enrolled in the study; all had been postmenopausal for at least
1 year and all reported climacteric symptoms accompanied by increased levels of follicle-
stimulating hormone (" 30 m-i.u./ml) and luteinizing hormone (" 20 m-i.u./ml), and a reduction
in oestradiol (! 25 pg/ml). All women were given hormone replacement therapy with
transdermal oestradiol, either patch (50 lg/24 h) or gel (1 mg/day), cyclically combined with oral
dihydrogesterone (10 mg/day for 12 days/month, on days 19–30 of the month). ANP and BNP
were measured directly in plasma samples with specific and sensitive immunoradiometric assays
before and after hormone replacement therapy (transdermal oestradiol combined with oral
dihydrogesterone). Body weight, arterial blood pressure and echocardiographic examination
values did not change after hormone replacement therapy. As expected, serum oestradiol
increased significantly and gonadotropins decreased as an effect of the hormone replacement
therapy. On average, both ANP and BNP had increased significantly after 3 months of hormone
replacement therapy [ANP: before treatment, 17–6‡9–6 pg/ml; after, 23–6‡5–6 pg/ml (Pfl
0–0173) ; BNP: before treatment, 12–6‡10–2 pg/ml; after, 19–8‡14–0 pg/ml (P! 0–0001)]. Our
study indicates that hormone replacement therapy for a period of 3 months induces a rise in the
circulating levels of cardiac natriuretic hormones in postmenopausal women. Our data also
suggest the working hypothesis that cardiac natriuretic peptides may play an important role in
mediating the cardioprotective effects of female steroid sex hormones in women throughout life.
INTRODUCTION
The incidence of cardiovascular diseases is significantly
lower in women of child-bearing age than in men,
whereas after menopause this difference disappears [1,2].
Furthermore, a cardioprotective role of oestrogen re-
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placement therapy in postmenopausal women has been
suggested in several studies [1,3–6].
An important pathophysiological mechanism in car-
diovascular diseases is the imbalance between the
vasoconstrictive}anti-natriuretic action of some neuro-
endocrine factors (including the renin–angiotensin–
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aldosterone system, vasopressin and the sympathetic
nervoussystem)andthecounter-regulatoryvasodilatory}
natriuretic effects of other factors, such as the car-
diac natriuretic peptides [7,8]. The relationship between
cardiac natriuretic hormones [i.e. atrial natriuretic pep-
tide (ANP) and brain natriuretic peptide (BNP)] and
female steroid sex hormones has been poorly investigated
in humans [1,9,10], although some studies suggest that
female sex steroids may have some influence on the
cardiac natriuretic hormone system.
Indeed, higher circulating levels of ANP and}or BNP
have been observed in women than in men [11–13]. In
addition, a 2-fold increase in plasma ANP levels has been
found during the last trimester of pregnancy and in
immediate puerperium [14,15], while conflicting results
concerning changes in plasma ANP or BNP levels during
the menstrual cycle have been reported [9,10,16–20]. In
some studies [17,20], circulating levels of cardiac natri-
uretic peptides were found to be significantly higher
during the follicular than the luteal phase of the menstrual
cycle, whereas in other studies [10,16,18,19] no
differences were observed. Conflicting results were also
obtained when ANP levels were measured in post-
menopausal women before and after hormone replace-
ment therapy: in one study [21] a significant decrease was
found, while in another no significant variations were
reported [22]. Finally, the plasma ANP level increased
significantly in premenopausal women after adminis-
tration of low-dose oral contraceptives [22].
In order to study the inter-relationship between female
steroid sex hormones and cardiac natriuretic peptides in
humans, we measured the plasma levels of ANP and
BNP by means of highly sensitive and specific immuno-
radiometric assay (IRMA) methods [11,13,23] in post-
menopausal women, both before and after hormone
replacement therapy. The data obtained from the group
of postmenopausal women undergoing hormone replace-
ment therapy have also been compared with a control
group of postmenopausal women well matched for age
and sodium intake.
MATERIALS AND METHODS
Experimental subjects
Informed consent was obtained from all women, who
had received detailed information concerning the aims
and nature of the study. The study was approved by the
Ethics and Scientific Committee of the CNR Clinical
Physiology Unit, Pisa, and was carried out in accordance
with the Declaration of Helsinki (1989) of the World
Medical Association.
Treated group
A total of 22 healthy postmenopausal women (non-
smokers ; mean age 51–9‡4–6 years and range 48–61
years ; body mass index 23–2‡2–5 kg[mw#), who were
about to start hormone replacement therapy for relief of
postmenopausal symptoms, were enrolled in the study.
Of these, 20 women had been postmenopausal for at least
1 year, and all reported climacteric symptoms accom-
panied by increases in the levels of follicle-stimulating
hormine (FSH) (" 30 m-i.u.}ml) and luteinizing hor-
mone (LH) (" 20 m-i.u.}ml) and a reduction in
oestradiol (! 25 pg}ml). The other two women were
undergoing surgical menopause due to uterine fibroids
(surgical operation performed at the age of 47 and 50
years respectively). During the study, all the women
strictly followed a personalized diet, without caloric
restriction (normocaloric), which was prescribed and
checked at regular intervals by a dietician, as reported
previously [10,24,25]. Furthermore, an M-mode, two-
dimensional Doppler echocardiographic examination
was performed before and after 3 months of hormone
repacement therapy.
Venous blood was drawn from each subject (fasting)
for basal circulating oestradiol, LH, FSH, ANP and BNP
evaluation. All the women were given hormone re-
placement therapy with transdermal oestradiol, patch
(50 lg}24 h) or gel (1 mg}day), combined cyclically with
oral dihydrogesterone (10 mg}day for 12 days}month
on days 19–30 of the month). Due to the large variability
in transdermal absorption, a blood venous sample was
obtained to assess plasma levels of oestradiol, FSH and
LH during the first 1 month of therapy. If oestradiol
concentrations were below the physiological range for
the follicular phase of the ovarian cycle, oestradiol gel
therapy was administered instead of the patch prep-
aration. After 3 months of treatment, blood was collected
again for the evaluation of the circulating hormones and
peptides described above. Plasma collection was per-
formed on the second day of the fourth patch of the
month and at the ninth hour after gel application during
the oestrogenic phase of the hormone replacement
therapy.
Since circulating levels of cardiac hormones (especially
ANP) show large variation in normal subjects due to
their short plasma half-lives, between five and seven
blood samples were collected from each woman over a
15-min period, using a venous catheter [9,10]. To
minimize the variation in hormone plasma concen-
trations, for each woman the mean of all ANP or BNP
values measured in samples collected was then used for
statistical analysis.
Control group
Plasma ANP and BNP levels were measured in a control
group of postmenopausal women, including 21 healthy
postmenopausal women well matched for age (mean age
53–1‡4–6 years ; range 48–62 years) and sodium intake
with the group of postmenopausal women undergoing
hormone replacement therapy.
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Table 1 Body weight, arterial blood pressure and hormone levels in 22 postmenopausal
women (age 51–9‡4–6 years) before and after hormone replacement therapy
SBP, systolic blood pressure ; DBP, diastolic blood pressure. Values are means‡S.D. P values were determined by paired
t-tests ; n.s., not significant.
Parameter Basal After HRT P value
Weight (kg) 61–0‡7–0 60–8‡6–7 n.s.
SBP (mmHg) 124–6‡15–2 129–0‡13–0 n.s.
DBP (mmHg) 72–3‡10–6 72–1‡9–7 n.s.
Oestradiol (pg/ml) 18–5‡8–2 63–6‡43–0 ! 0–0001
FSH (m-i.u./ml) 75–6‡21–8 38–6‡13–4 ! 0–0001
LH (m-i.u./ml) 36–4‡8–2 24–1‡8–3 ! 0–0001
ANP (pg/ml) 17–6‡9–6 23–6‡5–6 0–0173
BNP (pg/ml) 12–6‡10–2 19–8‡14–0 ! 0–0001
All subjects were non-obese and had arterial blood
pressure in the normal range; they were free from acute
diseases, and they denied any serious disease in the past,
as well as the use of any drug during the 3 weeks prior to
the study. In particular, the group of postmenopausal
women denied any past use of sex steroid hormones for
relief of postmenopausal symptoms. All of them had
normal values for the main plasma parameters (including
creatinine, urea nitrogen, glucose, uric acid, albumin,
enzymes, electrolytes and haemoglobin), and normal
erythrocyte and leucocyte counts and urine analysis.
Assay methods
Plasma samples
After collection, blood samples (10 ml) were immediately
put into ice-chilled disposable polypropylene tubes
containing aprotinin (500 kallikrein-inhibitory units}ml
of plasma) and EDTA (1 mg}ml of plasma). Plasma
samples were separated rapidly by centrifugation at
2000 g for 5 min at 4 °C, and then frozen and stored
at fi20 °C in 1 ml aliquots in polypropylene tubes until
assay.
Hormone assays
Plasma levels of ANP and BNP were measured with two-
site (sandwich) IRMA methods, which do not require a
preliminary step for extraction or purification of plasma
samples (direct assay), as described previously in detail
[11,13,23]. These methods were chosen for this study due
to their high degree of sensitivity (approx. 2–3 pg}ml),
precision (between-assay variability ranging from 5% to
12%) and accuracy, since it is well known that the
competitive immunoassay methods usually employed for
the assay of cardiac natriuretic peptides are unable to
measure ANP and BNP concentrations in the normal
range with acceptable precision [9,26,27].
Serum oestradiol was measured by means of a com-
petitive chemiluminescent immunoassay kit (Immulite
Analyzer2 ; DPC), and LH and FSH levels were
measured using non-competitive chemiluminescent
Figure 1 Individual values for plasma ANP levels measured
in the 22 postmenopausal women before and after 3 months
of hormone replacement therapy
The horizontal lines indicate mean values. The level of statistical significance with
respect to the basal value was calculated by paired t test after logarithmic
transformation of the original values.
immunoassay kits (Access2 ; Sanofi Pasteur). For all these
methods the intra-assay coefficient of variation was
% 10%, and the between-assay coefficient of variation
was % 15%, for the range of serum hormone concen-
trations observed in the present study.
Statistical analysis
Statistical analysis was carried out using the Stat-View
5–0.1 program (1992–1998; SAS Institute Inc., Cary, NC,
U.S.A.). Because ANP and BNP levels in healthy subjects
are not normally distributed, the logarithmic transform-
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Figure 2 Individual values for plasma BNP levels measured
in the 22 postmenopausal women before and after 3 months
of hormone replacement therapy
The horizontal lines indicate mean values. The level of statistical significance with
respect to the basal value was calculated by paired t test after logarithmic
transformation of the original values.
Figure 3 Plasma levels of ANP and BNP in seven post-
menopausal women in the basal condition, and after 3 and 12
months of hormone replacement therapy (HRT)
The level of statistical significance with respect to the basal value for BNP
concentrations was calculated after repeated-measures ANOVA by the Fisher ’s
protected least significant difference test.
ation of data was used for statistical analysis when
necessary. For comparisons between two paired groups,
Student’s paired t test was used (i.e. data reported in
Table 1 and Figures 1 and 2). Moreover, data from more
than two independent groups were analysed by repeated-
measures ANOVA (i.e. data reported in Figure 3). The
results are expressed as means‡S.D. if not otherwise
stated.
RESULTS
Mean weight, arterial blood pressure and hormonal
values in postmenopausal women before and after 3
months of hormone replacement therapy are reported in
Table 1. As expected, serum oestradiol levels increased
significantly and gonadotropin levels decreased as an
effect of the hormone replacement therapy.
Body weight and blood pressure did not differ before
and after hormone replacement therapy (Table 1). Fur-
thermore, echocardiographic examination did not show
any changes in wall thickness and}or chamber diameters
after 3 months of hormone replacement therapy (e.g. left
atrium: before, 35–0‡3–4 mm; after, 36–2‡3–1 mm;
septum thickness : before, 9–00‡0–82 mm; after, 8–83‡
0–94 mm; thickness of posterior wall : before, 9–00‡
1–00 mm; after, 9–92‡1–17 mm; diastolic left ventri-
cular diameter : before, 43–9‡3–2 mm; after, 44–6‡
2–5 mm).
Figures 1 and 2 report individual ANP and BNP levels
measured before and after 3 months of hormone re-
placement therapy in the 22 postmenopausal women. On
average, levels of both ANP (›34–1%) and BNP
(›57–1%) increased significantly after hormone replace-
ment therapy. However, BNP levels increased in a
significantly greater number of postmenopausal women
(v#-square test : P fl 0–0089) after hormone replacement
therapy (21 women out of 22; 95–5%) compared with
ANP values (14 women out 22; 63–6%).
Furthermore, it was possible to collect plasma samples
from seven women after a total of 12 months of hormone
replacement therapy for the assay of cardiac natriuretic
peptides (Figure 3). BNP levels were significantly
increased with respect to the basal values throughout the
entire study period, up to 12 months of treatment with
hormone replacement therapy (repeated-measures
ANOVA: P fl 0–0236).
Finally, the group of postmenopausal women under-
going hormone replacement therapy had mean circu-
lating levels of cardiac natriuretic peptides that were
higher (although only BNP values showed a significant
difference) than those of a control group comprising 21
healthy postmenopausal women well matched for age
and sodium intake [values for control group: BNP,
11–1‡9–1 pg}ml (P fl 0–0389 by unpaired t test compared
with hormone replacement therapy group) ; ANP,
19–8‡11–7 pg}ml (P fl 0–3603)].
DISCUSSION
Our data indicate that hormone replacement therapy
with transdermal oestrogens for 3 months, which
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achieves serum oestradiol concentrations in the physio-
logical range along with a fall in serum gonadotropin
levels, induces an increase in circulating levels of cardiac
natriuretic peptides.
To our knowledge, only two studies have investigated
the effects of hormone replacement therapy on circu-
lating levels of ANP in postmenopausal women. One
study [22] reported no significant increase in ANP levels
in 17 postmenopausal women during hormone replace-
ment treatment. Another study [21] found a significant
decrease in 13 postmenopausal women after 3 months of
hormone replacement therapy. At present, it is difficult
to explain these conflicting results. However, these two
studies [21,22] and ours used different experimental
protocols (with regard to both sample collection and
drugs administered) as well as assay methods (RIA
compared with IRMA). To our knowledge, no previous
study has examined the effects of hormone replacement
therapy on circulating levels of BNP.
Previous studies from our laboratory have indicated
that no significant changes over a period of several days
(or months) are observed in plasma levels of cardiac
natriuretic hormones, including those of normal cycling
women studied in different phases of the menstrual cycle,
when a study protocol requiring 5–7 blood samples
collected at rest over a 15-min period is used [9,10].
In the present study, we also found increased plasma
levels of cardiac natriuretic peptides after 12 months
of hormone replacement therapy in seven postmeno-
pausal women. Furthermore, BNP levels in post-
menopausal women undergoing hormone replacement
therapy were found to be significantly increased with
respect to those in a control (untreated) group of
postmenopausal women. These data, taken as a whole,
strongly suggest that the increase in plasma levels of
cardiac natriuretic hormones after hormone replacement
therapy is due to a specific pharmacological effect, and
therefore should not be considered to be a spurious
finding and}or an aleatory event, such as the regression-
to-the-mean phenomenon. It is also important to note
that an aleatory event would affect both ANP and
BNP systems in a similar manner, while in our
study BNP levels showed a greater increase than those
of ANP; this suggests a specific pharmacological effect
on this hormone system.
An increase in circulating levels of ANP and BNP may
theoretically be due to either an increase in hormone
production}secretion or a decrease in peptide degra-
dation (i.e. via specific neutral peptidases and clearance
receptors) [9,27–31].
Since collection of plasma for hormone assays was
performed during the oestrogenic phase of the hormone
replacement therapy, the stimulatory effects on the
ANP}BNP hormone system, observed in the present
study, may be due to an oestrogenic action. As reviewed
previously [1], there are two possible ways in which
cardiac natriuretic peptide production can be affected by
oestrogens : one is by a direct effect on cardiac gene
expression and}or release, and the other is by one or
more mediator mechanisms. Some authors have
suggested that the increase in cardiac natriuretic peptide
levels during oestrogen treatment may be secondary to
activation of the renin–angiotensin–aldosterone system,
which in turn affects vascular compliance and plasma
volume [1,22]. However, no significant increases in serum
renin activity or aldosterone levels were found in
postmenopausal women after hormone replacement
therapy [22].
Since the best-known stimulatory mechanisms for the
release and}or production of cardiac natriuretic peptides
are the stretch and hypertrophic growth of myocardio-
cytes [28–30], a possible effect of hormone replacement
therapy on the cardiac camera dimension, the thickness
of the parietal wall and the interventricular septum was
evaluated by means of Doppler echocardiographic exam-
ination. However, no significant changes in cardiac
camera dimension, the thickness of the parietal wall or
the interventricular septum were found after 3 months of
hormone replacement therapy in the postmenopausal
women we studied.
As yet, no comprehensive and systematic study is
available on the effects of sex steroid hormones on ANP
and BNP gene expression and release [1] ; therefore it is
still unclear whether gonadal hormones can directly
affect the production and secretion of cardiac natriuretic
peptides by the human heart. There are also no data
available concerning a possible inhibitory effect of sex
steroid hormones on the mechanisms responsible for
degradation of the cardiac natriuretic hormones. How-
ever, such an effect would seem to be an unlikely
explanation for data obtained in the present study,
because a non-specific inhibition of degradative pathways
would be expected to increase the plasma concentrations
of both ANP and BNP, and most probably those of ANP
to a greater extent than those of BNP, because the rate of
turnover of ANP is greater than that of BNP [31].
The incidence of cardiovascular disease is significantly
lower in women during their child-bearing years than in
men, whereas after menopause this difference disappears
[1,2]. Furthermore, cardiovascular mortality in post-
menopausal women receiving hormone replacement
therapy is about 30–50% lower than in their untreated
counterparts [1,2]. For these reasons, it was suggested
that female sex steroid hormones may have a cardio-
protective effect in women, even if their mechanism of
action is unclear at present [1]. However, several studies
indicate that the cardioprotective effect of hormone
replacement therapy in menopausal women may be due,
at least partly, to the effects of sex steroid hormones
(especially oestrogens) on vascular tone and}or endo-
thelial function [1–6,32].
The cardiac natriuretic hormones have several im-
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portant physiological actions, offering some beneficial
effects in cardiovascular disorders [1,8,9,28–31], includ-
ing: (a) a decrease in blood pressure ; (b) an increase in
natriuresis and diuresis ; (c) inhibition of the sympathetic
nervous system and of the release or action of several
hormones, including aldosterone, angiotensin II, endo-
thelins, renin and vasopressin. It is important to underline
that some of these endogenous substances are also
produced in endothelial cells and}or other vascular
tissues ; consequently, cardiac natriuretic hormones
should also have a protective effect on endothelium
function by inhibiting the action of some of these
neurohormones. Indeed, vascular tissues, as well as
platelets [33], are rich in specific receptors for cardiac
natriuretic peptides ; in addition, the endothelium
produces and secretes a peptide of the same family of
cardiac natriuretic hormones, called C-type natriuretic
peptide [34].
Therefore it can be hypothesized that the cardio-
protective action of hormone replacement therapy in
postmenopausal women may be mediated, at least in part,
by increased circulating levels of cardiac natriuretic
peptides. Indeed, some studies suggest that steroid sex
hormones significantly affect the gene expression and
production of cardiac natriuretic peptides, but no data are
available to indicate whether this is the result of direct or
indirect effects of female sex steroid hormones [1].
However, irrespective of the pharmacological mechanism
of hormone replacement therapy, its effect seems to be
more pronounced on levels of BNP compared with
ANP, probably because ventricular myocardial tissue is
affected more than are atrial cardiomyocytes. This is not
surprising, because it is well known that ANP
production}secretion in atrial myocardiocytes is regu-
lated differently from BNP production}secretion in
ventricular myocardial tissue [29].
In conclusion, our present study indicates that 3
months of transdermal oestrogen replacement therapy
induces a rise in the circulating levels of cardiac natriuretic
peptides in postmenopausal women. Our data also
suggest the working hypothesis that cardiac natriuretic
peptides may play an important role in mediating the
cardioprotective effects of female steroid sex hormones in
women throughout life.
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